1246529-32-7

Basic information

• Product Name: MPI-0479605
• Synonyms: MPI-0479605;N6-cyclohexyl-N2-(2-methyl-4-morpholinophenyl)-9H-purine-2,6-diamine;MPI0479605 HCl;N6-Cyclohexyl-N2-[2-methyl-4-(4-morpholinyl)phenyl]-9H-purine-2,6-diamine
• CAS NO: 1246529-32-7
• Molecular Formula: C₂₂H₂₉N₇O
• Molecular Weight: 407.52
• Product Categories: Inhibitors
• Mol File: 1246529-32-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 745.8±70.0 °C(Predicted)
• Appearance: /
• Density: 1.318±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: Soluble in DMSO
• PKA: 10.52±0.10(Predicted)
• CAS DataBase Reference: MPI-0479605(CAS DataBase Reference)
• NIST Chemistry Reference: MPI-0479605(1246529-32-7)
• EPA Substance Registry System: MPI-0479605(1246529-32-7)

Safety Data

• Hazardous Substances Data: 1246529-32-7(Hazardous Substances Data)

Usage

Description

MPI-0479605 is a potent and ATP-competitive inhibitor of the mitotic kinase MPS1 (IC50 = 1.8 nM). It is selective for MPS1 over a panel of 79 kinases at a concentration of 500 nM. MPI-0479605 induces time-dependent degradation of cyclin B and securin and decreases phosphorylation of BUBR1 resulting in failed cytokinesis in HeLa cells arrested by nocodazole . It also causes misalignment of chromosomes at the anaphase plate and aneuploidy in A549 cells and slows cell cycle progression of HCT116 and COLO 205 cells irrespective of p53 activity. MPI-0479605 (30-150 mg/kg) reduces tumor volume in an HCT116 mouse colon cancer xenograft model in a dose-dependent manner.

references

[1] tardif k d, rogers a, cassiano j, et al. characterization of the cellular and antitumor effects of mpi-0479605, a small-molecule inhibitor of the mitotic kinase mps1. molecular cancer therapeutics, 2011, 10(12): 2267-2275.

Upstream product

• 5451-40-1 2,6 dichloropurine 
• 108-91-8 cyclohexylamine 
• 220679-09-4 4-(3-methyl-4-nitrophenyl)morpholine 
• 581-00-0 2-Methyl-4-morpholin-4-ylphenylamine 
• 1246532-45-5 2-chloro-N-cyclohexyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 39639-45-7 (2-chloro-9H-purin-6-yl)-cyclohexyl-amine 
• 1246532-46-6 N₆-cyclohexyl-N₂-(2-methyl-4-morpholin-4-yl-phenyl)-9-(tetrahydropyran-2-yl)-9H-purine-2,6-diamine 
• 1246532-35-3 2-methyl-4-morpholin-4-yl-phenylamine hydrochloride 

Relevant articles and documents

Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Efforts to optimize biological activity, novelty, selectivity and oral bioavailability of Mps1 inhibitors, from a purine based lead MPI-0479605, are described in this Letter. Mps1 biochemical activity and cytotoxicity in HCT-116 cell line were improved. On-target activity confirmation via mechanism based G2/M escape assay was demonstrated. Physico-chemical and ADME properties were optimized to improve oral bioavailability in mouse.